


Product data sheet



MedKoo Cat#: 207191 Name: BDTX-1535 CAS#: 2607829-38-7 Chemical Formula: C ₃₀ H ₃₀ ClFN ₆ O ₂ Exact Mass: 560.2103 Molecular Weight: 561.06	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:

BDTX-1535 is a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC). BDTX-1535 selectively targets, irreversibly binds to, and inhibits the activity of various EGFR alterations and mutations, including certain intrinsic and acquired resistance mutations. This prevents EGFR-mediated signaling in susceptible tumor cells. BDTX-1535 may mitigate resistance to osimertinib, the standard of care for EGFR-mutant non-small cell lung cancer. It could also potentially treat central nervous system metastases, having shown preclinical efficacy in glioblastoma.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	100	178.24

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.78 mL	8.91 mL	17.82 mL
5 mM	0.36 mL	1.78 mL	3.56 mL
10 mM	0.18 mL	0.89 mL	1.78 mL
50 mM	0.04 mL	0.18 mL	0.36 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

To be determined

In vivo study

- BDTX-1535 Goes after Osimertinib Resistance. Cancer Discov. 2021 Dec 1;11(12):2952-2953. doi: 10.1158/2159-8290.CD-NB2021-0395. PMID: 34702733.

7. Bioactivity

Biological target:

PY-60 is a specific activator of YAP transcriptional activity that targets annexin ANXA2 (Kd = 1.4 μM). PY-60 directly binds to ANXA2 and antagonizes its repression of YAP activity.

In vitro activity

To be determined

Product data sheet



In vivo activity

BDTX-1535 may mitigate resistance to osimertinib, the standard of care for EGFR-mutant non-small cell lung cancer. It could also potentially treat central nervous system metastases, since it demonstrated preclinical efficacy in glioblastoma.

Reference: Cancer Discov. 2021 Dec 1;11(12):2952-2953. <https://pubmed.ncbi.nlm.nih.gov/34702733/>

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.